Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate …
Over the last 12 months, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $20M and sold $0 worth of Acrivon Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $33.68M and sold $97,579 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $360.01M.
The last purchase of 2,353,000 shares for transaction amount of $20M was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑11.
2024-04-11 | 10 percent owner | 2.35M 8.4743% | $8.50 | $20M | -17.22% | |||
2023-06-26 | Sale | 10 percent owner | 16 <0.0001% | $12.93 | $207 | -48.66% | ||
2023-06-15 | Sale | 10 percent owner | 2,056 0.0106% | $12.14 | $24,960 | -39.33% | ||
2023-06-14 | Sale | 10 percent owner | 893 0.0046% | $12.13 | $10,832 | -38.40% | ||
2023-06-13 | Sale | 10 percent owner | 3,000 0.0156% | $12.30 | $36,900 | -40.28% | ||
2023-06-12 | Sale | 10 percent owner | 2,000 0.0105% | $12.34 | $24,680 | -40.91% | ||
2022-11-17 | 3.39M 17.9519% | $12.50 | $42.37M | -21.95% | ||||
2022-11-17 | 10 percent owner | 400,000 2.1185% | $12.50 | $5M | -21.95% |
PERCEPTIVE ADVISORS LLC | 10 percent owner | 5360858 17.2174% | $6.71 | 1 | 0 | |
RA CAPITAL MANAGEMENT, L.P. | 4384206 14.0807% | $6.71 | 1 | 0 | <0.0001% | |
Chione Ltd | 10 percent owner | 3848632 12.3606% | $6.71 | 1 | 5 | <0.0001% |